Andrea E. Tijhuis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Andrea E. Tijhuis has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
- Floris Foijer
European Research Institute for the Biology of Ageing (ERIBA), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
10 shared publications - Diana Carolina Johanna Spierings
European Research Institute for the Biology of Ageing, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands
6 shared publications - Andreas Villunger
Institute for Developmental Immunology, Biocenter, Medical University of Innsbruck, 6020 Innsbruck, Austria
5 shared publications - Fabian Schuler
Institute for Developmental Immunology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria
4 shared publications - Gerlinde Karbon
Institute for Developmental Immunology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria
4 shared publications Manuel Haschka
Institute for Developmental Immunology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria
3 shared publications
Latest Publications
- 13 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (46)
Aneuploidy impairs B cell development but accelerates their MYC-driven transformation
Chromosomal instability (CIN) is an established driver of aneuploidy and cell death. Here, we investigate the role of apoptosis as a barrier against CIN-driven aneuploidy in B lymphocytes. We found that impairment of their spindle assembly checkpoint via deletion of Mitotic Arrest Deficient 2-Like 1 or mutation of Monopolar Spindle 1 kinase curtails B cell survival. A CRISPR screen identified intermediates of mitochondrial apoptosis as critical, which we confirmed in vivo by overexpression of a B cell–restricted BCL2 transgene, outperforming loss of P53 . Notably, cell death inhibition by BCL2 was insufficient to cause aneuploidy-driven B cell transformation, while loss of P53 strongly synergized with tumors featuring stochastic aneuploidies. In contrast, high cell death rates rapidly select for specific karyotypes, facilitating aneuploid tumor cell survival in E μ -Myc transgenic mice. Hence, cell death inhibition fails to allow CIN-driven aneuploidies to prevail. In contrast, BCL2-regulated apoptosis selects viable aneuploid tumor karyotypes in the presence of oncogenic MYC, a notion with implications for the clinical use of BCL2-targeting therapies.
- 13 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (46)
Aneuploidy impairs B cell development but accelerates their MYC-driven transformation
Chromosomal instability (CIN) is an established driver of aneuploidy and cell death. Here, we investigate the role of apoptosis as a barrier against CIN-driven aneuploidy in B lymphocytes. We found that impairment of their spindle assembly checkpoint via deletion of Mitotic Arrest Deficient 2-Like 1 or mutation of Monopolar Spindle 1 kinase curtails B cell survival. A CRISPR screen identified intermediates of mitochondrial apoptosis as critical, which we confirmed in vivo by overexpression of a B cell–restricted BCL2 transgene, outperforming loss of P53 . Notably, cell death inhibition by BCL2 was insufficient to cause aneuploidy-driven B cell transformation, while loss of P53 strongly synergized with tumors featuring stochastic aneuploidies. In contrast, high cell death rates rapidly select for specific karyotypes, facilitating aneuploid tumor cell survival in E μ -Myc transgenic mice. Hence, cell death inhibition fails to allow CIN-driven aneuploidies to prevail. In contrast, BCL2-regulated apoptosis selects viable aneuploid tumor karyotypes in the presence of oncogenic MYC, a notion with implications for the clinical use of BCL2-targeting therapies.
- Top Cited PapersOpen Access
- 13 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (11) , eaeb1611
Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS–chemokine–myeloid axis
Chromosomal instability (CIN), a pervasive feature of esophageal adenocarcinoma (EAC), drives tumor aggressiveness and metastasis. CIN stimulates the cGAS–STING pathway, typically linked to antitumor immunity. However, despite the high CIN burden in EAC, the cGAS–STING pathway remains largely intact. To address this paradox, we interrogated multiple esophageal cancer models, finding myeloid-attracting chemokines—with CXCL8 as a prominent hit—as conserved CIN-driven targets in EAC. Using multiplexed immunofluorescence microscopy, we quantified ongoing CIN in human EAC tumors by measuring cGAS-positive micronuclei, validated by whole-genome sequencing. Coupling in situ CIN detection with single-nucleus RNA sequencing and multiplex immunophenotyping of human EAC, we link CIN to tumor-intrinsic innate immune activation, CXCL8 expression, and myeloid cell–mediated immunosuppression. In patients with EAC, CIN high , myeloid-dominated tumors correlate with poor outcomes and aberrant cGAS–STING signaling. These insights explain the counterintuitive maintenance of cGAS–STING and highlight the disruption of the CIN–cGAS–inflammation axis as a potential therapeutic strategy in EAC.
- 13 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (11) , eaeb1611
Top Cited PapersOpen AccessChromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS–chemokine–myeloid axis
Chromosomal instability (CIN), a pervasive feature of esophageal adenocarcinoma (EAC), drives tumor aggressiveness and metastasis. CIN stimulates the cGAS–STING pathway, typically linked to antitumor immunity. However, despite the high CIN burden in EAC, the cGAS–STING pathway remains largely intact. To address this paradox, we interrogated multiple esophageal cancer models, finding myeloid-attracting chemokines—with CXCL8 as a prominent hit—as conserved CIN-driven targets in EAC. Using multiplexed immunofluorescence microscopy, we quantified ongoing CIN in human EAC tumors by measuring cGAS-positive micronuclei, validated by whole-genome sequencing. Coupling in situ CIN detection with single-nucleus RNA sequencing and multiplex immunophenotyping of human EAC, we link CIN to tumor-intrinsic innate immune activation, CXCL8 expression, and myeloid cell–mediated immunosuppression. In patients with EAC, CIN high , myeloid-dominated tumors correlate with poor outcomes and aberrant cGAS–STING signaling. These insights explain the counterintuitive maintenance of cGAS–STING and highlight the disruption of the CIN–cGAS–inflammation axis as a potential therapeutic strategy in EAC.
- 1 March 2026
- Published by IATED Academy in INTED Proceedings
- Vol. 1, 1458
CONSTRUCTIVE BY DESIGN? EVALUATING AN AI FEEDBACK COACH IN COLLABORATIVE LEARNING CONTEXTS
- 1 March 2026
- Published by IATED Academy in INTED Proceedings
- Vol. 1, 1458
CONSTRUCTIVE BY DESIGN? EVALUATING AN AI FEEDBACK COACH IN COLLABORATIVE LEARNING CONTEXTS
- 21 March 2025
- Published by EMBL-EBI
Benchmarking scRNA-seq copy number variation callers
BioStudies – one package for all the data supporting a study
- 21 March 2025
- Published by EMBL-EBI
Benchmarking scRNA-seq copy number variation callers
BioStudies – one package for all the data supporting a study
- Open Access
- 28 May 2024
- Published by Springer Nature in EMBO Reports
- Vol. 25 (6) , 2743-2772
Chronic spindle assembly checkpoint activation causes myelosuppression and gastrointestinal atrophy
Interference with microtubule dynamics in mitosis activates the spindle assembly checkpoint (SAC) to prevent chromosome segregation errors. The SAC induces mitotic arrest by inhibiting the anaphase-promoting complex (APC) via the mitotic checkpoint complex (MCC). The MCC component MAD2 neutralizes the critical APC cofactor, CDC20, preventing exit from mitosis. Extended mitotic arrest can promote mitochondrial apoptosis and caspase activation. However, the impact of mitotic cell death on tissue homeostasis in vivo is ill-defined. By conditional MAD2 overexpression, we observe that chronic SAC activation triggers bone marrow aplasia and intestinal atrophy in mice. While myelosuppression can be compensated for, gastrointestinal atrophy is detrimental. Remarkably, deletion of pro-apoptotic Bim/Bcl2l11 prevents gastrointestinal syndrome, while neither loss of Noxa/Pmaip or co-deletion of Bid and Puma/Bbc3 has such a protective effect, identifying BIM as rate-limiting apoptosis effector in mitotic cell death of the gastrointestinal epithelium. In contrast, only overexpression of anti-apoptotic BCL2, but none of the BH3-only protein deficiencies mentioned above, can mitigate myelosuppression. Our findings highlight tissue and cell-type-specific survival dependencies in response to SAC perturbation in vivo.
- 28 May 2024
- Published by Springer Nature in EMBO Reports
- Vol. 25 (6) , 2743-2772
Open AccessChronic spindle assembly checkpoint activation causes myelosuppression and gastrointestinal atrophy
Interference with microtubule dynamics in mitosis activates the spindle assembly checkpoint (SAC) to prevent chromosome segregation errors. The SAC induces mitotic arrest by inhibiting the anaphase-promoting complex (APC) via the mitotic checkpoint complex (MCC). The MCC component MAD2 neutralizes the critical APC cofactor, CDC20, preventing exit from mitosis. Extended mitotic arrest can promote mitochondrial apoptosis and caspase activation. However, the impact of mitotic cell death on tissue homeostasis in vivo is ill-defined. By conditional MAD2 overexpression, we observe that chronic SAC activation triggers bone marrow aplasia and intestinal atrophy in mice. While myelosuppression can be compensated for, gastrointestinal atrophy is detrimental. Remarkably, deletion of pro-apoptotic Bim/Bcl2l11 prevents gastrointestinal syndrome, while neither loss of Noxa/Pmaip or co-deletion of Bid and Puma/Bbc3 has such a protective effect, identifying BIM as rate-limiting apoptosis effector in mitotic cell death of the gastrointestinal epithelium. In contrast, only overexpression of anti-apoptotic BCL2, but none of the BH3-only protein deficiencies mentioned above, can mitigate myelosuppression. Our findings highlight tissue and cell-type-specific survival dependencies in response to SAC perturbation in vivo.
- Open Access
- 29 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (13) , eadk0564
Extra centrosomes delay DNA damage–driven tumorigenesis
Deregulated centrosome numbers are frequently found in human cancer and can promote malignancies in model organisms. Current research aims to clarify if extra centrosomes are cause or consequence of malignant transformation, and if their biogenesis can be targeted for therapy. Here, we show that oncogene-driven blood cancer is inert to genetic manipulation of centrosome numbers, whereas the formation of DNA damage–induced malignancies is delayed. We provide first evidence that this unexpected phenomenon is connected to extra centrosomes eliciting a pro-death signal engaging the apoptotic machinery. Apoptosis induction requires the PIDDosome multi-protein complex, as it can be abrogated by loss of any of its three components, Caspase-2 , Raidd/Cradd , or Pidd1 . BCL2 overexpression equally blocks cell death, documenting for the first time induction of mitochondrial apoptosis downstream of extra centrosomes. Our findings demonstrate context-dependent effects of centrosome amplification during transformation and ask to adjust current belief that extra centrosomes are intrinsically pro-tumorigenic.
- 29 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (13) , eadk0564
Open AccessExtra centrosomes delay DNA damage–driven tumorigenesis
Deregulated centrosome numbers are frequently found in human cancer and can promote malignancies in model organisms. Current research aims to clarify if extra centrosomes are cause or consequence of malignant transformation, and if their biogenesis can be targeted for therapy. Here, we show that oncogene-driven blood cancer is inert to genetic manipulation of centrosome numbers, whereas the formation of DNA damage–induced malignancies is delayed. We provide first evidence that this unexpected phenomenon is connected to extra centrosomes eliciting a pro-death signal engaging the apoptotic machinery. Apoptosis induction requires the PIDDosome multi-protein complex, as it can be abrogated by loss of any of its three components, Caspase-2 , Raidd/Cradd , or Pidd1 . BCL2 overexpression equally blocks cell death, documenting for the first time induction of mitochondrial apoptosis downstream of extra centrosomes. Our findings demonstrate context-dependent effects of centrosome amplification during transformation and ask to adjust current belief that extra centrosomes are intrinsically pro-tumorigenic.
- 26 March 2024
- Published by EMBL-EBI
Source Data for EMBOR-2023-58131V2
BioStudies – one package for all the data supporting a study
- 26 March 2024
- Published by EMBL-EBI
Source Data for EMBOR-2023-58131V2
BioStudies – one package for all the data supporting a study
- Open Access
- 20 February 2024
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 223 (4)
Tunable DNMT1 degradation reveals DNMT1/DNMT3B synergy in DNA methylation and genome organization
DNA methylation (DNAme) is a key epigenetic mark that regulates critical biological processes maintaining overall genome stability. Given its pleiotropic function, studies of DNAme dynamics are crucial, but currently available tools to interfere with DNAme have limitations and major cytotoxic side effects. Here, we present cell models that allow inducible and reversible DNAme modulation through DNMT1 depletion. By dynamically assessing whole genome and locus-specific effects of induced passive demethylation through cell divisions, we reveal a cooperative activity between DNMT1 and DNMT3B, but not of DNMT3A, to maintain and control DNAme. We show that gradual loss of DNAme is accompanied by progressive and reversible changes in heterochromatin, compartmentalization, and peripheral localization. DNA methylation loss coincides with a gradual reduction of cell fitness due to G1 arrest, with minor levels of mitotic failure. Altogether, this system allows DNMTs and DNA methylation studies with fine temporal resolution, which may help to reveal the etiologic link between DNAme dysfunction and human disease.
- 20 February 2024
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 223 (4)
Open AccessTunable DNMT1 degradation reveals DNMT1/DNMT3B synergy in DNA methylation and genome organization
DNA methylation (DNAme) is a key epigenetic mark that regulates critical biological processes maintaining overall genome stability. Given its pleiotropic function, studies of DNAme dynamics are crucial, but currently available tools to interfere with DNAme have limitations and major cytotoxic side effects. Here, we present cell models that allow inducible and reversible DNAme modulation through DNMT1 depletion. By dynamically assessing whole genome and locus-specific effects of induced passive demethylation through cell divisions, we reveal a cooperative activity between DNMT1 and DNMT3B, but not of DNMT3A, to maintain and control DNAme. We show that gradual loss of DNAme is accompanied by progressive and reversible changes in heterochromatin, compartmentalization, and peripheral localization. DNA methylation loss coincides with a gradual reduction of cell fitness due to G1 arrest, with minor levels of mitotic failure. Altogether, this system allows DNMTs and DNA methylation studies with fine temporal resolution, which may help to reveal the etiologic link between DNAme dysfunction and human disease.
- Open Access
- 26 January 2024
- Published by Springer Nature in The EMBO Journal
- Vol. 43 (5) , 666-694
Weakened APC/C activity at mitotic exit drives cancer vulnerability to KIF18A inhibition
The efficacy of current antimitotic cancer drugs is limited by toxicity in highly proliferative healthy tissues. A cancer-specific dependency on the microtubule motor protein KIF18A therefore makes it an attractive therapeutic target. Not all cancers require KIF18A, however, and the determinants underlying this distinction remain unclear. Here, we show that KIF18A inhibition drives a modest and widespread increase in spindle assembly checkpoint (SAC) signaling from kinetochores which can result in lethal mitotic delays. Whether cells arrest in mitosis depends on the robustness of the metaphase-to-anaphase transition, and cells predisposed with weak basal anaphase-promoting complex/cyclosome (APC/C) activity and/or persistent SAC signaling through metaphase are uniquely sensitive to KIF18A inhibition. KIF18A-dependent cancer cells exhibit hallmarks of this SAC:APC/C imbalance, including a long metaphase-to-anaphase transition, and slow mitosis overall. Together, our data reveal vulnerabilities in the cell division apparatus of cancer cells that can be exploited for therapeutic benefit.
- 26 January 2024
- Published by Springer Nature in The EMBO Journal
- Vol. 43 (5) , 666-694
Open AccessWeakened APC/C activity at mitotic exit drives cancer vulnerability to KIF18A inhibition
The efficacy of current antimitotic cancer drugs is limited by toxicity in highly proliferative healthy tissues. A cancer-specific dependency on the microtubule motor protein KIF18A therefore makes it an attractive therapeutic target. Not all cancers require KIF18A, however, and the determinants underlying this distinction remain unclear. Here, we show that KIF18A inhibition drives a modest and widespread increase in spindle assembly checkpoint (SAC) signaling from kinetochores which can result in lethal mitotic delays. Whether cells arrest in mitosis depends on the robustness of the metaphase-to-anaphase transition, and cells predisposed with weak basal anaphase-promoting complex/cyclosome (APC/C) activity and/or persistent SAC signaling through metaphase are uniquely sensitive to KIF18A inhibition. KIF18A-dependent cancer cells exhibit hallmarks of this SAC:APC/C imbalance, including a long metaphase-to-anaphase transition, and slow mitosis overall. Together, our data reveal vulnerabilities in the cell division apparatus of cancer cells that can be exploited for therapeutic benefit.
- 1 January 2024
- Published by The Company of Biologists in Journal of Cell Science
- Vol. 137 (1)
Characterizing chromosomal instability-driven cancer evolution and cell fitness at a glance
Chromosomal instability (CIN), an increased rate of chromosome segregation errors during mitosis, is a hallmark of cancer cells. CIN leads to karyotype differences between cells and thus large-scale heterogeneity among individual cancer cells; therefore, it plays an important role in cancer evolution. Studying CIN and its consequences is technically challenging, but various technologies have been developed to track karyotype dynamics during tumorigenesis, trace clonal lineages and link genomic changes to cancer phenotypes at single-cell resolution. These methods provide valuable insight not only into the role of CIN in cancer progression, but also into cancer cell fitness. In this Cell Science at a Glance article and the accompanying poster, we discuss the relationship between CIN, cancer cell fitness and evolution, and highlight techniques that can be used to study the relationship between these factors. To that end, we explore methods of assessing cancer cell fitness, particularly for chromosomally unstable cancer.
- 1 January 2024
- Published by The Company of Biologists in Journal of Cell Science
- Vol. 137 (1)
Characterizing chromosomal instability-driven cancer evolution and cell fitness at a glance
Chromosomal instability (CIN), an increased rate of chromosome segregation errors during mitosis, is a hallmark of cancer cells. CIN leads to karyotype differences between cells and thus large-scale heterogeneity among individual cancer cells; therefore, it plays an important role in cancer evolution. Studying CIN and its consequences is technically challenging, but various technologies have been developed to track karyotype dynamics during tumorigenesis, trace clonal lineages and link genomic changes to cancer phenotypes at single-cell resolution. These methods provide valuable insight not only into the role of CIN in cancer progression, but also into cancer cell fitness. In this Cell Science at a Glance article and the accompanying poster, we discuss the relationship between CIN, cancer cell fitness and evolution, and highlight techniques that can be used to study the relationship between these factors. To that end, we explore methods of assessing cancer cell fitness, particularly for chromosomally unstable cancer.